These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20095333)

  • 1. [Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting: a randomized controlled trial].
    Han YL; Zhang ZL; Li Y; Wang SL; Jing QM; Wang ZL; Wang DM
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2240-4. PubMed ID: 20095333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study.
    Patti G; Tomai F; Melfi R; Ricottini E; Macrì M; Sedati P; Giardina A; Aurigemma C; Leporace M; D'Ambrosio A; Di Sciascio G
    J Am Coll Cardiol; 2013 Apr; 61(13):1379-87. PubMed ID: 23490041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis.
    Lotfi A; Schweiger MJ; Giugliano GR; Murphy SA; Cannon CP;
    Am Heart J; 2008 May; 155(5):954-8. PubMed ID: 18440347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
    Saw J; Steinhubl SR; Berger PB; Kereiakes DJ; Serebruany VL; Brennan D; Topol EJ;
    Circulation; 2003 Aug; 108(8):921-4. PubMed ID: 12925453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
    Saw J; Brennan DM; Steinhubl SR; Bhatt DL; Mak KH; Fox K; Topol EJ;
    J Am Coll Cardiol; 2007 Jul; 50(4):291-5. PubMed ID: 17659194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Frundi D; Stratz C; Valina CM; Bestehorn HP; Büttner HJ; Neumann FJ
    Thromb Haemost; 2008 Jan; 99(1):174-81. PubMed ID: 18217151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting].
    Han YL; Li CY; Li Y; Kang J; Yan CH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Sep; 35(9):788-92. PubMed ID: 18070466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.
    Brophy JM; Babapulle MN; Costa V; Rinfret S
    Am Heart J; 2006 Aug; 152(2):263-9. PubMed ID: 16875906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
    Kim JS; Kim J; Choi D; Lee CJ; Lee SH; Ko YG; Hong MK; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Lee NH; Cho YH; Cho DK; Jang Y
    JACC Cardiovasc Interv; 2010 Mar; 3(3):332-9. PubMed ID: 20298994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Rodis FI; Elisaf M; Goudevenos JA; Tselepis AD
    Circulation; 2004 Mar; 109(11):1335-8. PubMed ID: 15023882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
    Wenaweser P; Windecker S; Billinger M; Cook S; Togni M; Meier B; Haeberli A; Hess OM
    Am J Cardiol; 2007 Feb; 99(3):353-6. PubMed ID: 17261397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; McCabe CH; Cairns R; Tonkin AM; Sacks FM; Jackson G; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1405-10. PubMed ID: 16226162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4.
    Polena S; Gupta MP; Shaikh H; Zazzali K; Coplan N; Gintautas J; Labana SS; Soffer D
    Proc West Pharmacol Soc; 2008; 51():60-2. PubMed ID: 19544679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin].
    Pokrovskaia EV; Vaulin NA; Gratsianskiĭ NA; Averkov OV; Deev AD
    Kardiologiia; 2003; 43(1):7-18. PubMed ID: 12891281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
    Ridker PM; Morrow DA; Rose LM; Rifai N; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2005 May; 45(10):1644-8. PubMed ID: 15893181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.